Vaccitech Plc
Vaccitech Plc:
Proprietary ChAdOx (prime) and MVA (boost) technology platform induces CD8+ T cell and antibody immune responses to treat and prevent infectious diseases and cancer. Broad therapeutic pipeline. Ph1/2a full efficacy for VTP-300 (HBV functional cure) expected H22022 and VTP-200 (high-risk HPV therapeutic) Ph1/2a interim efficacy data expected 4Q2022. Encouraging prostate cancer, 5T4 immunotherapeutic data. Ph1/2a NSCLC MAGE-NYESO immunotherapeutic interim data expected Q42023m first patient dosed Q12022. $15M royalty revenue during Q42021 from AstraZeneca's commercial sales of Vaxzevria® (out-licensed ChAdOx COVID-19 vaccine). Avidea Technologies (private) acquisition expands product pipeline with complementary SNAPvax platform
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
COVID-19, Immunotherapy, Infectious Disease, Oncology
Finance
Revenues
Industry
Biotechnology
Investement Strategy
Under the Radar
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Vaccine
Website:
Profiles:
Address:
The Schrodinger Building, Heatley Road
The Oxford Science Park
Oxford, OX4 4GE
United Kingdom
The Oxford Science Park
Oxford, OX4 4GE
United Kingdom
More info:
My account:
Company Participants at Vaccitech Virtual KOL Event, Jan. 2022
- William Enright, Chief Executive Officer
Top 10 Holders of Vaccitech Plc Sponsored ADR
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| M&G Investment Management Ltd. | 3.12 | 1,088,597 | 4.96 | 13F | 3/31/22 |
| DC Funds LP | 1.84 | 642,204 | 2.93 | 13F | 3/31/22 |
| Liontrust Investment Partners LLP | 1.72 | 600,000 | 2.73 | 13F | 3/31/22 |
| Liontrust Investment Management Ltd. | 1.72 | 600,000 | 2.73 | Funds | 12/31/21 |
| BlueCrest Capital Management (UK) LLP | 1.56 | 542,673 | 2.47 | 13F | 3/31/22 |
| The Johns Hopkins University | 0.31 | 107,968 | 0.49 | 13F | 3/31/22 |
| Millennium Management LLC | 0.20 | 68,656 | 0.31 | 13F | 3/31/22 |
| Ipswich Investment Management Co., Inc. | 0.15 | 52,375 | 0.24 | 13F | 3/31/22 |
| Morgan Stanley Capital Services LLC | 0.02 | 7,016 | 0.03 | 13F | 3/31/22 |
| Geode Capital Management LLC | 0.02 | 6,221 | 0.03 | Funds | 2/28/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.